# Auristone

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/auristone

- Industry: Biotechnology
- Headquarters: Singapore
- Website: www.auristone.com
- Total disclosed funding: $4.6M
- Latest round: Seed (Mar 4, 2025)
- Investors on record: 4

## About

Established in 2021 and based in Singapore, Auristone is a biotech company that focuses on epigenomic analysis. The company's scientific co-founders are Prof. Patrick Tan and Prof. Teh Bin Tean, experts in the fields of epigenomics and gastric cancer (GC), as well as genomics, translational research and drug discovery, respectively.

The company is dedicated to clinical and academic epigenomic research. The company's self-developed sequencing NGS (Next-generation sequencing) test platform EPI-Call, which provides epigenomic information about the tumor microenvironment and predicts patient response to immunotherapy.

## Funding rounds

- Seed, Mar 4, 2025, $2.7M — SEEDS Capital, elev8.vc, Genedant Capital, Exact Genomics Pte. Ltd.
- Seed, Dec 26, 2023, $2M — elev8.vc, Genedant Capital

## Investors

- elev8.vc (https://capitalatlas.ai/funds/elev8-vc) — Seed
- Genedant Capital (https://capitalatlas.ai/funds/genedant-capital) — Seed
- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Seed
- Exact Genomics Pte. Ltd. — Seed